enGene Therapeutics (ENGN) vs Palisade Bio (PALI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Palisade Bio (PALI) has outperformed enGene Therapeutics (ENGN) over the past year, losing 60.6% versus a loss of 75.0%. Palisade Bio is the larger company by market cap ($150.7 million vs $116.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENGN | PALI |
|---|---|---|
| Share price | $1.74 | $0.8399 |
| Market cap | $116.61M | $150.74M |
| 1-day change | -1.14% | -9.24% |
| YTD return | -80.73% | -64.26% |
| 1-year return | -75.00% | -60.57% |
| 5-year return | — | -99.95% |
| P/E ratio (TTM) | — | 0.91 |
| EPS (TTM) | $-2.07 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-117.30M | $-16.78M |
| 52-week high | $12.25 | $2.86 |
| 52-week low | $1.40 | $0.8381 |
| Distance from 52-week high | -85.80% | -70.63% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +146.55% | +935.84% |
| Average volume | 1.12M | 3.19M |
| Shares outstanding | 67.02M | 179.28M |
| Employees | 81 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PALI has outperformed ENGN by 14.4 percentage points over the past year.
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
ENGN vs PALI FAQ
Which is bigger, enGene Therapeutics or Palisade Bio?
Palisade Bio (PALI) is larger, with a market capitalization of $150.74M compared with $116.61M for enGene Therapeutics (ENGN).
Which stock has performed better over the past year, ENGN or PALI?
PALI returned -60.57% over the past 12 months, compared with -75.00% for ENGN (price return, excluding dividends). Past performance does not predict future results.
Are enGene Therapeutics and Palisade Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.